PIPELINE
Our Portfolio
We work on the best targets for patients
We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on immunological and orphan diseases. We select targets with low translation risk through genetic association, pathway linked patient selection or immune signature stratification.

Click Target For More Info

Description
Target Type Indication
MC2 GPCR Orphan endocrine disorders
GPR65 GPCR IBD
Gasdermin Intracellular complexes Broad immunology
KCC2 Solute carriers Epilepsy including rare epilepsy
SLC15A4 Solute carriers Lupus and other IFN-opathies
Progress
Discovery Lead ID Lead Optimisation Preclinical
MC2
Insurmountable ACTH antagonism for a best-in-class profile in rare endocrine disorders.
GPR65
First-in-class molecules driving novel anti-inflammatory biology in Inflammatory Bowel Disease.
Gasdermin
First-in-class Gasdermin D inhibitors – a pipeline in a product.
KCC2
First-in-class solute carrier activator reducing seizures in epilepsy including rare epilepsies
SLC15A4
First-in-class solute carrier inhibitor against a highly validated target in Lupus and other IFN-opathies

PIPELINE

Need more information about our pipeline?

Contact Us